Literature DB >> 3792431

Pharmacokinetic approach to equilibrium between ketanserin and ketanserin-ol.

A Van Peer, R Woestenborghs, L Embrechts, J Heykants.   

Abstract

The metabolic reduction-oxidation equilibrium between ketanserin and ketanserin-ol was studied after oral dosing of both substances to two healthy volunteers. Comparison of plasma Cmax and AUCs indicated that the equilibrium was shifted towards ketanserin-ol. There is evidence that ketanserin-ol elimination is the slowest step dictating the terminal half-life of ketanserin.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3792431     DOI： 10.1007/bf00981134

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


  8 in total

1.  Bioavailability and pharmacokinetics of ketanserin in elderly subjects.

Authors:  M Kurowski
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

2.  Pharmacokinetics of ketanserin and its metabolite ketanserin-ol in man after intravenous, intramuscular and oral administration.

Authors:  J Heykants; A Van Peer; R Woestenborghs; S Gould; J Mills
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

3.  Acute blood-pressure-lowering effect of ketanserin.

Authors:  J De Cree; H Verhaegen; J Symoens
Journal:  Lancet       Date:  1981-05-23       Impact factor: 79.321

4.  Pharmacokinetics of ketanserin in man.

Authors:  I W Reimann; P O Okonkwo; U Klotz
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

5.  Pharmacokinetics and pharmacodynamics of the 5-HT2 receptor antagonist ketanserin in man.

Authors:  D Trenk; A Mosler; W Kirch; T Meinertz; E Jähnchen
Journal:  J Cardiovasc Pharmacol       Date:  1983 Nov-Dec       Impact factor: 3.105

6.  High-performance liquid chromatographic assay with fluorometric detection of ketanserin, a new antihypertensive agent and serotonin S2 antagonist in human plasma, blood and urine.

Authors:  P O Okonkwo; I W Reimann; R Woestenborghs; U Klotz
Journal:  J Chromatogr       Date:  1983-02-11

Review 7.  Antihypertensive properties of ketanserin (R 41 468).

Authors:  P M Vanhoutte; J M Van Nueten; J Symoens; P A Janssen
Journal:  Fed Proc       Date:  1983-02

8.  5-HT, alpha-adrenoceptors, and blood pressure. Effects of ketanserin in essential hypertension and autonomic insufficiency.

Authors:  G J Wenting; A J Woittiez; A J Man in't Veld; M A Schalekamp
Journal:  Hypertension       Date:  1984 Jan-Feb       Impact factor: 10.190
  8 in total
  9 in total

Review 1.  Clinical pharmacokinetics of ketanserin.

Authors:  B Persson; J Heykants; T Hedner
Journal:  Clin Pharmacokinet       Date:  1991-04       Impact factor: 6.447

Review 2.  Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

3.  Acute and chronic ketanserin in essential hypertension: antihypertensive mechanisms and pharmacokinetics.

Authors:  R Donnelly; H L Elliott; P A Meredith; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1987-11       Impact factor: 4.335

4.  Pharmacokinetics of a nootropic agent, BMY-21502, and its metabolites in beagle dogs.

Authors:  N Srinivas; S Kaul
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Jan-Mar       Impact factor: 2.441

5.  Pharmacokinetics of ketanserin in patients with essential hypertension.

Authors:  B Persson; A Pettersson; T Hedner
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

6.  Could the increased antihypertensive efficacy of ketanserin in the elderly be due to altered pharmacokinetics?

Authors:  S E Gould; J H Silas; J Hosie
Journal:  Cardiovasc Drugs Ther       Date:  1990-01       Impact factor: 3.727

7.  The pharmacokinetics of ketanserin after a single dose and at steady-state in hypertensive subjects.

Authors:  P C Waller; G T Tucker; L E Ramsay
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

8.  Ketanserin pharmacokinetics in patients with renal failure.

Authors:  J N Barendregt; A Van Peer; J G Van Der Hoeven; J C Van Oene; Y I Tjandra
Journal:  Br J Clin Pharmacol       Date:  1990-06       Impact factor: 4.335

9.  Pharmacokinetics of ketanserin in patients with cirrhosis.

Authors:  D Lebrec; A Hadengue; C Gaudin; J C Levron; B Fraitag; P Berthelot; J P Benhamou
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.